search results for

refine results

sort by

Date
Relevance

result type

Articles
Video

Wires
Press Releases

Sen. Grassley: Need more transparency in drug pricing

Sen. Charles Grassley (R-Iowa), reacts to what Mylan CEO Heather Bresch had to say about the EpiPen pricing outrage.

Source: CNBC.com

Sen. Grassley: I want a written response from Mylan

Sen. Charles Grassley (R-Iowa), reacts to what Mylan CEO Heather Bresch had to say about the EpiPen pricing outrage.

Source: CNBC.com

Soaring drug prices: Are middlemen to blame?

Vishnu Lekraj, Morningstar senior equity analyst, discusses the role of the pharmacy benefit managers, or PBMs, and whether the "middlemen" are the ones to blame for drug price hikes.

Source: CNBC.com

Welch: Bresch should have apologized

Suzy Welch, LinkedIn contributing editor, discusses Mylan CEO Heather Bresch and what she had to say about the controversy surrounding Mylan's pricing of the EpiPen.

Source: CNBC.com

Shares of Clovis surge on positive FDA news

Shares of Clovis surge on positive FDA news, CNBC's Melissa Lee reports.

Source: CNBC.com

Trump flip-flopping on immigration?

Jacob Monty, Houston-based immigration attorney and GOP activist, shares his take on Donald Trump's change of tone on immigration.

Source: CNBC.com

EpiPen pricing impact

How is the EpiPen outrage impacting families, parents and children who need these products as protection against fatal allergy attacks? CNBC's Kate Kelly and Sue Herera discuss how its affecting their own children.

Source: CNBC.com

Toll Brothers CEO on new home sales

Doug Yearley, Toll Brothers CEO, discusses his company's earnings report, new home sales data and the state of the U.S. economy.

Source: CNBC.com

One Miami doctor's fight against Zika

Having treated over a dozen cases already, Dr. Christine Curry, University of Miami, describes what it is like to treat pregnant women with Zika.

Source: CNBC.com

Remodeling spending to reach all-time high?

A new report forecasts home remodeling this year will top records set during the housing boom. CNBC's Brian Sullivan discusses. Robert Wetenhall, RBC Capital Markets Homebuilding and Building Products analyst, and Todd Tomalak, John Burns Consulting VP, weigh in.

Source: CNBC.com